#United States #Miami #Early Cancer Detection #Santé Ventures #beHuman

beHuman Secures $4 Million Seed Funding

beHuman, a physician-led platform focused on preventive healthcare, has announced a significant milestone with the acquisition of $4 million in seed funding. This investment, mainly led by Santé Ventures with additional participation from DHVP.io, is set to propel beHuman's mission to enhance early cancer detection, especially for underserved populations across the United States.

Founded on the principles of accessibility and equity in healthcare, beHuman aims to tackle the challenge of late cancer diagnoses, particularly among communities that are often neglected by traditional healthcare systems. CEO Steve Yaskin emphasized the importance of early detection, stating that many insured Americans receive diagnoses too late due to systemic barriers that prevent them from accessing essential screenings. With this new funding, beHuman plans to expand its reach beyond its current operations in the northern and southeastern regions of the U.S., ensuring that its services are accessible to a larger audience.

One of the critical innovations driving beHuman's initiative is its vertically-integrated approach to preventive care. Unlike existing solutions that cater mainly to affluent consumers, beHuman targets a broader audience—insured patients who may face obstacles such as geographic constraints, administrative complexities, or a general mistrust of the healthcare system. By simplifying the screening process and reducing administrative burdens through its advanced diagnostic technologies, beHuman is positioned to significantly enhance access to care.

The company's innovative model seamlessly combines virtual clinical care, advanced diagnostics, and continuous health monitoring. This integration allows beHuman to proactively identify cancer risks and guide patients through their screening processes. Additionally, its agentic AI platform automates key workflows, including eligibility verification and appointment scheduling, which not only alleviates clinician workload but also ensures the delivery of physician-guided care.

Data privacy is a top priority for beHuman, especially in underserved communities where concerns about data misuse are prevalent. The platform ensures strict data governance and transparency, safeguarding patient information exclusively for healthcare purposes.

Early data from beHuman indicates that their cancer detection rates surpass national averages. By encouraging patients to engage early in their healthcare journey, beHuman has managed to identify risks that would often remain undetected until much later. Moreover, most major insurance plans cover their services, thus removing financial barriers and making preventive care more accessible.

With this latest funding, beHuman aims to:

• - Expand its operations into more states, thereby reaching more underserved patients.
• - Build deeper collaborations with top diagnostic laboratories to streamline the detection process.
• - Enhance the AI platform for improved efficiency in preventive care workflows.
• - Scale their virtual care teams to serve more patients effectively.

With a commitment to equitable healthcare solutions, beHuman is determined that prevention must be accessible and trustworthy to be effective. To learn more about beHuman's innovative approach to healthcare, you can visit their official website at www.behuman.health.

About beHuman

beHuman is a healthcare platform that leverages AI to make early cancer detection available to a wider audience. By blending virtual healthcare services, cutting-edge diagnostics, and user-friendly automated workflows, beHuman aims to help patients, particularly from underserved backgrounds, identify potential cancer risks early and navigate the screening process with ease. The service is widely accepted by most insurance providers, facilitating easier access to preventive care across the U.S.

About Santé Ventures

Santé Ventures, established in 2006, specializes in healthcare and life sciences investments. With over $1 billion in capital under management, the firm is dedicated to supporting early-stage companies that are innovating in medical technology, biotechnology, and digitally enabled healthcare services. Their notable investments highlight their commitment to transforming healthcare delivery and improving outcomes through innovation.